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Running title: Homocysteine metabolism and Multiple Sclerosis 
 
Abstract 
Methylenetetrahydrofolate reductase (MTHFR) is necessary for the synthesis of methionine and S-
adenosylmethionine, which is necessary for CNS (re-)myelination. The MTHFR variant c.1298A>C was 
associated with the development of Relapsing Remitting Multiple Sclerosis (RRMS) in a German 
population. This study aimed at analyzing whether further genetic variants of methionine metabolism are 
associated with the development or the clinical course of RRMS. Therefore, genomic DNA of 147 serial 
German RRMS patients and 147 matched healthy controls was genotyped for five polymorphic variants of 
methionine metabolism. Statistical analyses were performed using multivariate binary and linear 
regression analyses. We show that the insertion allele of cystathionine beta-synthase (CBS) 
c.844_855ins68bp and the G-allele of reduced folate carrier 1 (RFC1) c.80G>A were associated with an 
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earlier age of onset of MS, suggesting gene-dose-effects (median age of onset in years: 25-26-32; 
standardized regression coefficient Beta: 0.216; p=0.030, and 29-31-35 years; Beta: 0.282; p=0.005, 
respectively). Conclusively, mutant variants of CBS and RFC1 may be associated with the age of RRMS 
onset. Since methionine metabolism can be manipulated by supplementation of vitamins and amino acids, 
our data provide a rationale for novel ideas of preventive and therapeutic strategies in RRMS. 
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Introduction 
Multiple sclerosis (MS) is a complex neurological disease that affects the central nervous system (CNS) 
and is characterized by inflammation, demyelination and neurodegeneration. Despite intensive research, 
both the etiology and the pathogenesis of MS are not completely understood. The current concepts suggest 
a multifactorial etiology with interplay between immunological, environmental and genetic factors. 
Furthermore, MS has been explored with regard to methionine-homocysteine metabolism as an alliance of 
genetics and environment. For example, homocysteine plasma levels are increased in relapsing remitting 
MS (RRMS) patients [1]. In addition, vitamin B12 deficiency may be associated with RRMS, and severe 
vitamin B12 deficiency shares some neurodegenerative and inflammatory pathophysiological 
characteristics with RRMS including central demyelination [2]. Vitamin B12 is necessary for the 
remethylation of neurotoxic homocysteine to methionine. Methionine is a semi-essential amino acid that 
can be activated to S-adenosylmethionine (SAM) by methionine-adenosyltransferase (MAT, EC 2.5.1.6; 
figure 1). S-adenosylmethionine serves as ubiquitous methyl donor and is essential for several 
components of the myelin sheet, such as myelin basic protein or phospholipids. In experimental and 
clinical studies, anti-inflammatory and analgesic effects of SAM have been shown [3]. Transmethylation 
of S-adenosylmethionine results in S-adenosylhomocysteine, which becomes hydrolyzed to homocysteine, 
a reactive neuro- and vasculotoxic amino acid [4,5]. Homocysteine can be metabolized in two different 
pathways: First, cystathionine beta-synthase (CBS, EC 4.2.1.22), which depends on pyridoxal-phosphate 
(vitamin B6), can convert homocysteine to cystathionine. In the other pathway, methionine can be 
regenerated from homocysteine in the CNS via methyltetrahydrofolate-homocysteine S-methyltransferase 
(MTR, EC 2.1.1.13), which depends on cobalamin (vitamin B12) and 5-methyltetrahydrofolate. 
Transcobalamin 2 (Tc2) acts as a transporter protein of cobalamin. Reduced folate carrier 1 (RFC1) is a 
transmembrane transporter protein mainly expressed in the brain [6]. Dihydrofolate reductase (DHFR, EC 
1.5.1.3) reduces the precursor dihydrofolic acid (DHF) to the active component tetrahydrofolate and is 
thereby essential for the availability of folates in the CNS [7]. 
Interestingly, this metabolism shows high inter-individual variety depending on renal function, individual 
  Homocysteine metabolism and Multiple Sclerosis 
 
4 
 
vitamin and methionine uptake and on the genetic profile of methionine-homocysteine metabolism, i.e. on 
the expression of allelic variants with functional consequences for the encoded enzymes, transporter 
proteins or carriers. Severe mutations affecting the enzymes of methionine-homocysteine metabolism can 
lead to CNS demyelination [8]. Thus, we hypothesize that variants with functional consequences impact 
chronic inflammatory demyelinating diseases. Previously we observed that the allelic variant 5,10-
methylenetetrahydrofolate reductase (MTHFR) c.1298A>C was associated with the incidence of RRMS in 
a German cohort [9]. In the present study we extended the analysis of that cohort by testing whether five 
further functionally relevant variants of methionine-homocysteine metabolism are associated with the 
development or the age of onset of RRMS (table 1).  
 
Materials and methods 
Study population 
The study population consisted of 147 serial German patients of Caucasian origin with RRMS according 
to McDonald criteria [10] (106 female; mean age ± standard deviation (SD): 31.5±8.7 years). The patients 
were recruited from the Department of Neurology, University of Bonn, Germany. In addition, we 
analyzed 147 German age- and gender-matched healthy local controls of Caucasian origin without 
apparent signs or a history of neurological or immunological disease (106 female; 30.5±7.3 years). All 
individuals of the present study were unrelated. The local ethics committee approved the study and 
informed written consent was received from all subjects. 
 
Genotyping 
DNA was extracted from peripheral leukocytes using QIAquick DNA extracting Kit (Qiagen, Hilden, 
Germany). Genomic DNA was amplified by PCR (Thermocycler T Professional, Biometra, Göttingen, 
Germany; Taq Polymerase and Polymerase buffer, Roche Diagnostics, Basel, Switzerland; Primers, 
Microsynth, Balgach, Switzerland) followed by restriction enzyme digestion (New England Biolabs, 
Ipswich, USA)  and agarose gel electrophoresis. The PCR and restriction analysis conditions were 
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described previously [11-15]. 
 
Statistical analysis 
Data were analysed with the Statistical Package for the Social Sciences (SPSS statistics, Version 16). To 
test the independent association of the genetic variants on development of RRMS, all variants were 
simultaneously analysed together with age and gender as covariables in multivariate binary regression 
analysis. Accordingly, the association with age of onset was analysed using multivariate linear regression. 
Statistical significance was defined with p < 0.05. 
 
Results  
There were no significant differences concerning gender (χ2 = 0.263, p = 0.627) or age (F = 0.88, p = 
0.350) between patients and controls. The distribution of genotypes did not deviate from the Hardy-
Weinberg equilibrium. Allele frequencies of patients and controls were similar (table 2). However, the 
wildtype G allele of RFC1 c.80G>A was associated with an earlier age of RRMS onset, suggesting a gene 
dose effect (AA-AG-GG: 35-31-29; standardized regression coefficient Beta: 0.282; p=0.005, table 3). 
Additionally, the mutant CBS c.844_855ins68bp allele carrying the insertion (“ins”-allele) was associated 
with an earlier age of RRMS onset, also suggesting a gene dose effect (del/del-del/ins-ins/ins, median age 
of onset in years: 32-26-25; standardized regression coefficient Beta: 0.216; p=0.030). The other allelic 
variants did not reveal a significant difference in the age of MS onset.  
 
Discussion 
This study indicates an association of variants of CBS and RFC1 with the age of RRMS onset. The 
corresponding proteins are involved in methionine metabolism that is necessary for CNS myelination. In 
the CNS of mice, CBS is highly expressed in the hippocampus and cerebellum, whereas expression levels 
are unknown for human CNS [12,16]. The incomplete tandem repeat CBS c.844_855ins68bp leads to 
splice variants of CBS mRNA associated with higher CBS expression and lower homocysteine plasma 
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levels (figure 1) [13,14]. As a likely consequence, reduced amounts of homocysteine are metabolized via 
the alternative pathway, i.e. remethylation to methionine and S-adenosylmethionine. By reducing the (re-) 
methylation capacity of the CNS, this may lead to an earlier clinical manifestation of demyelinating 
diseases in predisposed individuals.  
RFC1 acts as a transmembrane transporter protein for 5-methyltetrahydrofolate and is thereby essential for 
folate distribution within the CNS. The RFC1 missense variant c.80G>A (p.R27H) might impact the CNS 
folate levels [17] and since folate is a cofactor for methionine synthesis, this might result in lower (re-) 
methylation capacity, analogue to CBS c.844_855ins68bp.  
Vitamin B12 has two functions in human metabolism: it functions as a cofactor for methylmalonyl CoA-
mutase for the synthesis of succinyl-CoA and as a cofactor for methionine synthesis. Previous studies 
report vitamin B12 deficiency in patients with RRMS [18-20] and a specific association between the age 
of onset of first neurological symptoms of MS and vitamin B12 metabolism [21]. Our data suggest that 
also genetic factors of methionine metabolism may be relevant for RRMS etiology or pathology. 
Methionine metabolism can easily be manipulated by the supplementation of vitamins and amino acids. 
Therefore, the re-evaluation of our results in independent studies may be reasonable to search for 
nutritional strategies to influence demyelinating diseases.  
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Tables 
 
Table 1 – Genetic variants analyzed in this study 
 
Allelic variant Effect Reference 
cystathionine beta-synthase  
c.844_855ins68bp 
splice alteration increasing 
the transcript and expression 
level 
Linnebank et al., 2001 
dihydrofolate reductase  
c.594+59del19bp 
intronic deletion supposedly 
affecting the transcript level 
Johnson et al., 2004 
methyltetrahydrofolate-
homocysteine S-
methyltransferase 
c.2756A>G 
missense mutation  p.D919G Leclerc et al., 1996 
reduced folate carrier 1  
c.80G>A 
missense mutation p.R27H Yates et al., 2005 
transcobalamin 2  
c.776C>G 
missense mutation p.P259R Afman et al., 2002 
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Table 2 – Frequencies of the allelic variants in patients and controls. There is no statistical 
significant difference in allelic frequencies between patients and control. 
 
 Genotype     Wald; p 
CBS c.844_845ins68bp del/del del/ins ins/ins   
Patients 0.79 0.20 0.01  
0.817; 0.366 
Controls 0.83 0.17 0  
 
DHFR c.594+59del19bp del/del del/ins ins/ins   
Patients 0.10 0.61 0.29  
0.010; 0.921 
Controls 0.20 0.48 0.32  
 
MTR c.2756 A>G  AA AG GG   
Patients 0.62 0.33 0.05  
0.357; 0.550 
Controls 0.70 0.23 0.07  
      
RFC1 c.80 G>A GG GA AA   
Patients 0.33 0.48 0.19  
0.842; 0.359 
Controls 0.44 0.36 0.20  
 
Tc2 c.776 C>G CC CG GG   
Patients 0.29 0.45 0.26  
2.69; 0.101 
Controls 0.37 0.46 0.17  
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Table 3 – RFC1 and CBS genotypes and age of onset. The wildtype G allele of RFC1 c.80G>A was 
associated with an earlier age of RRMS onset, suggesting a gene dose effect (AA-AG-GG: 35-31-29; 
standardized regression coefficient Beta: 0.282; p=0.005, table 3). Additionally, the mutant CBS 
c.844_855ins68bp allele carrying the insertion (“ins”-allele) was associated with an earlier age of RRMS 
onset, also suggesting a gene dose effect (del/del-del/ins-ins/ins, median age of onset in years: 32-26-25; 
standardized regression coefficient Beta: 0.216; p=0.030). The other allelic variants did not reveal a 
significant difference in the age of MS onset. Median age of first symptoms of MS ± 1 standard deviation. 
 
 
RFC1 c.80G>A AA GA GG  Beta; p 
Median age of MS onset  35 ± 14 31 ± 9 29 ± 8  0.282; 0.005 
 
CBS c.844_845ins68bp del/del del/ins ins/ins   
Median age of MS onset 32 ± 9 26 ± 6 25 ± 8  0.216; 0.030  
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Figure 1 - The sulfur-containing amino acid methionine can be activated by methionine-
adenosyltransferase (MAT) to S-adenosylmethionine (AdoMet), which is an ubiquitous methyl-group 
donor e.g. for myelin sheet components like phospholipids or myelin basic protein. The degradation 
product of AdoMet is S-adenosylhomocysteine (AdoHcy), which becomes hydrolyzed to homocysteine in 
a reversible reaction. Homocysteine can either be transsulfurated by vitamin B6-dependent CBS or 
remethylated to methionine and AdoMet via methyltetrahydrofolate-homocysteine S-methyltransferase 
(MTR), which depends on vitamin B12 and 5-methyltetrahydrofolate (5-mTHF) as cofactors. The reduced 
folate carrier 1 (RFC1) acts as a transmembrane transport protein for 5-mTHF and is essential for folate 
uptake into the CNS. Dihydrofolate reductase (DHFR) reduces the precursor dihydrofolic acid (DHF) to 
the active tetrahydrofolate (THF), which is further converted into 5-methyltetrahydrofolate by 5,10-
methylenetetrahydrofolate reductase (MTHFR). Tc2 is as a transport protein for vitamin B12. 
 
 
 
 
 
